CLEC4C and CD4+/CD56+ hematodermic neoplasm: Distinct from other markers such as CD123 and CD56, which manifest across a spectrum of hematologic malignancies, CD303 is predominantly expressed on pDCs, thereby providing a potent diagnostic tool for identifying malignant pDCs in BPDCN [58,59,60].